ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Otsuka, Innovent Biologics and Sanofi side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Otsuka×Innovent Biologics×Sanofi×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

OtsukaInnovent BiologicsSanofi
studies on the registry7842182,425
open to participants now5559104
phase 3 studies under way312361
reach primary completion within a year233664
programswith a study of their own in two years254080+12 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseOtsukaInnovent BiologicsSanofi
Phase 1

Otsuka: 12 of its 25 programs at phase 1

  1. VIS171phase 1
  2. 1-(12-(1 CARBOXYCYCLOPROPYL)DODECYL)CYCLOPROPANE-1-CARBOXYLIC acidphase 1
  3. ARC-02phase 1
  4. HBM7020phase 1
  5. SEP-380135phase 1

and 7 more — sign in to see them all

48%

Innovent Biologics: 14 of its 40 programs at phase 1

  1. IBI3033phase 1
  2. IBI3032phase 1
  3. IBI3042phase 1
  4. Anti-CEACAM5 Antibody-drug Conjugate IBI3020phase 1
  5. IBI115phase 1

and 9 more — sign in to see them all

35%
28%
Phase 2

Otsuka: 2 of its 25 programs at phase 2

  1. VIS954phase 2
  2. OPC 131461phase 2
8%

Innovent Biologics: 10 of its 40 programs at phase 2

  1. IBI3016phase 2
  2. telitaciceptphase 2
  3. IBI355phase 2
  4. IBI3002phase 2
  5. IBI3011phase 2

and 5 more — sign in to see them all

25%

Sanofi: 25 of its 80 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. efdoralprin alfaphase 2

and 20 more — sign in to see them all

31%
Phase 3

Otsuka: 10 of its 25 programs at phase 3

  1. sibeprenlimabphase 3
  2. ulotarontphase 3
  3. centanafadine hydrochloridephase 3
  4. futibatinibphase 3
  5. repinatrabitphase 3

and 5 more — sign in to see them all

40%
38%

Sanofi: 22 of its 80 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

28%
Approved, new studies

Otsuka: 1 of its 25 programs at approved, new studies

  1. Tolvaptanapproved, new study
4%

Innovent Biologics: 1 of its 40 programs at approved, new studies

  1. Teprotumumab N01approved, new study
3%

Sanofi: 11 of its 80 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Otsuka8 readouts · 3 phase 3·

Otsuka, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. difamilastphase 3 · Dec 0 · NCT07173478
  2. futibatinibphase 3 · Dec 0 · NCT05727176
·

Otsuka, Feb ’27: 1 program whose next study reaches primary completion

  1. repinatrabitphase 3 · Feb 9 · NCT07713758

Otsuka, Mar ’27: 1 program whose next study reaches primary completion

  1. sibeprenlimabphase 3 · Mar 13 · NCT06928142
·

Otsuka, May ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. centanafadine hydrochloridephase 3 · May 27 · NCT07759154
  2. zipalertinibphase 3 · May 27 · NCT05973773

Otsuka, Jun ’27: 1 program whose next study reaches primary completion

  1. zimberelimabphase 3 · Jun 0 · NCT04999761
·

Otsuka, Aug ’27: 1 program whose next study reaches primary completion

  1. 1-(12-(1 CARBOXYCYCLOPROPYL)DODECYL)CYCLOPROPANE-1-CARBOXYLIC acidphase 1 · Aug 25 · NCT07525960
··
Innovent Biologics18 readouts · 4 phase 3

Innovent Biologics, Nov ’26: 1 program whose next study reaches primary completion

  1. Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363phase 3 · Nov 30 · NCT07122687

Innovent Biologics, Dec ’26: 6 programs whose next study reaches primary completion, 3 in phase 3

  1. arcotatug tavatecanphase 3 · Dec 30 · NCT06238843
  2. GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003phase 3 · Dec 31 · NCT07764861
  3. IBI302phase 3 · Dec 31 · NCT06908876
  4. IBI3026early phase 1 · Dec 31 · NCT07327632
  5. IBI311phase 3 · Dec 31 · NCT07113262

and 1 more — sign in to see them all

Innovent Biologics, Jan ’27: 3 programs whose next study reaches primary completion

  1. IBI3016phase 2 · Jan 30 · NCT07838220
  2. IBI3034phase 1 · Jan 31 · NCT07886476
  3. telitaciceptphase 2 · Jan 31 · NCT07886476

Innovent Biologics, Feb ’27: 1 program whose next study reaches primary completion

  1. IBI3033phase 1 · Feb 10 · NCT07549984

Innovent Biologics, Mar ’27: 2 programs whose next study reaches primary completion

  1. IBI3042phase 1 · Mar 2 · NCT07842393
  2. IBI3002phase 2 · Mar 23 · NCT07399067

Innovent Biologics, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. tigulixostatphase 3 · Apr 30 · NCT07414394

Innovent Biologics, May ’27: 1 program whose next study reaches primary completion

  1. IBI3011phase 2 · May 11 · NCT07842497

Innovent Biologics, Jun ’27: 2 programs whose next study reaches primary completion

  1. IBI3031phase 1 · Jun 15 · NCT07622368
  2. IBI3028phase 1 · Jun 30 · NCT07589205

Innovent Biologics, Jul ’27: 1 program whose next study reaches primary completion

  1. IBI3035phase 1 · Jul 30 · NCT07591519
···
Sanofi29 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Otsuka

New programs 0

None

Reached a new phase 1

  • VIS954phase 2 · Oct 23 · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Study stopped 1

  • SEP-380135phase 1 · withdrawn Nov 19 · none of its studies left running“The trial was withdrawn prior to participant enrollment.” · NCT07455084

Primary completion later 3

Innovent Biologics

New programs 4

  • IBI3043phase 1 · first study · Oct 22
  • IBI3034phase 1 · first study · Oct 8 · Glomerulonephritis, IGA
  • telitaciceptphase 2 · first study · Sep 13 · Lupus Erythematosus, Systemic
  • IBI3046phase 1 · first study · Sep 3 · Obesity

Reached a new phase 2

  • IBI3011phase 2 · Sep 14 · Gout
  • IBI355phase 2 · Sep 13 · Sjogren's Syndrome

Study stopped 1

  • IBI356phase 2 · terminated Oct 27 · none of its studies left running“Sponsor Decision” · NCT07330934

Primary completion later 1

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Where they overlap

Conditions where at least two of them have programs: 23 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionOtsukaInnovent BiologicsSanofi
Dermatitis, Atopicall three · compare here

Otsuka in Dermatitis, Atopic: 1 program

  1. difamilastphase 3

Their studies: Otsuka’s studies of Dermatitis, Atopic in search

Innovent Biologics in Dermatitis, Atopic: 4 programs

  1. IBI3027phase 3
  2. IBI3002phase 2
  3. IBI356phase 2
  4. IBI3033phase 1

Their studies: Innovent Biologics’ studies of Dermatitis, Atopic in search

Sanofi in Dermatitis, Atopic: 5 programs

  1. lunsekimigphase 3
  2. amlitelimabphase 3
  3. itepekimabphase 3
  4. Dupilumab coformulated with berahyaluronidase alfaphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Dermatitis, Atopic in search

Carcinoma, Non-Small-Cell Lungall three · compare here

Otsuka in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. zipalertinibphase 3
  2. zimberelimabphase 3

Their studies: Otsuka’s studies of Carcinoma, Non-Small-Cell Lung in search

Innovent Biologics in Carcinoma, Non-Small-Cell Lung: 5 programs

  1. Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363phase 3
  2. sintilimabphase 3
  3. gimeracilphase 2
  4. Oxonic Acidphase 2
  5. Tegafurphase 2

Their studies: Innovent Biologics’ studies of Carcinoma, Non-Small-Cell Lung in search

Sanofi in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Tadalafilphase 3

Their studies: Sanofi’s studies of Carcinoma, Non-Small-Cell Lung in search

Lupus Erythematosus, Systemicall three · compare here

Otsuka in Lupus Erythematosus, Systemic: 1 program

  1. VIS171phase 1

Their studies: Otsuka’s studies of Lupus Erythematosus, Systemic in search

Innovent Biologics in Lupus Erythematosus, Systemic: 1 program

  1. telitaciceptphase 2

Their studies: Innovent Biologics’ studies of Lupus Erythematosus, Systemic in search

Sanofi in Lupus Erythematosus, Systemic: 2 programs

  1. frexalimabphase 3
  2. Anti-CD20 Bispecific Antibody DR-0201phase 1

Their studies: Sanofi’s studies of Lupus Erythematosus, Systemic in search

Colorectal Neoplasms2 of 3 · compare here–

Sanofi in Colorectal Neoplasms: 1 program

  1. tusamitamab sonditecanphase 1

Their studies: Sanofi’s studies of Colorectal Neoplasms in search

Asthma2 of 3 · compare here–

Innovent Biologics in Asthma: 1 program

  1. IBI3002phase 2

Their studies: Innovent Biologics’ studies of Asthma in search

Sanofi in Asthma: 5 programs

  1. lunsekimigphase 3
  2. duvakitugphase 3
  3. amlitelimabphase 3
  4. itepekimabphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Asthma in search

Psoriasis2 of 3 · compare here–

Innovent Biologics in Psoriasis: 2 programs

  1. picankibartphase 3
  2. IBI112phase 3

Their studies: Innovent Biologics’ studies of Psoriasis in search

Sanofi in Psoriasis: 3 programs

  1. balinatunfibphase 2
  2. belumosudilapproved, new study
  3. teplizumabapproved, new study

Their studies: Sanofi’s studies of Psoriasis in search

Stomach Neoplasms2 of 3 · compare here–

Innovent Biologics in Stomach Neoplasms: 4 programs

  1. sintilimabphase 3
  2. gimeracilphase 2
  3. Oxonic Acidphase 2
  4. Tegafurphase 2

Their studies: Innovent Biologics’ studies of Stomach Neoplasms in search

Sanofi in Stomach Neoplasms: 1 program

  1. Daxokafusp Alfaphase 2

Their studies: Sanofi’s studies of Stomach Neoplasms in search

Colitis, Ulcerative2 of 3 · compare here–

Innovent Biologics in Colitis, Ulcerative: 1 program

  1. IBI112phase 3

Their studies: Innovent Biologics’ studies of Colitis, Ulcerative in search

Sanofi in Colitis, Ulcerative: 3 programs

  1. duvakitugphase 3
  2. brivekimigphase 2
  3. balinatunfibphase 2

Their studies: Sanofi’s studies of Colitis, Ulcerative in search

Arthritis, Rheumatoid2 of 3 · compare here

Otsuka in Arthritis, Rheumatoid: 1 program

  1. HBM7020phase 1

Their studies: Otsuka’s studies of Arthritis, Rheumatoid in search

–

Sanofi in Arthritis, Rheumatoid: 2 programs

  1. balinatunfibphase 2
  2. sarilumabapproved, new study

Their studies: Sanofi’s studies of Arthritis, Rheumatoid in search

Autoimmune Diseases2 of 3 · compare here

Otsuka in Autoimmune Diseases: 2 programs

  1. sibeprenlimabphase 3
  2. VIS171phase 1

Their studies: Otsuka’s studies of Autoimmune Diseases in search

–

Sanofi in Autoimmune Diseases: 1 program

  1. belumosudilapproved, new study

Their studies: Sanofi’s studies of Autoimmune Diseases in search

Biliary Tract Neoplasms2 of 3 · compare here

Otsuka in Biliary Tract Neoplasms: 2 programs

  1. futibatinibphase 3
  2. zimberelimabphase 3

Their studies: Otsuka’s studies of Biliary Tract Neoplasms in search

Innovent Biologics in Biliary Tract Neoplasms: 1 program

  1. Anti-CTLA-4 Monoclonal Antibody IBI310phase 3

Their studies: Innovent Biologics’ studies of Biliary Tract Neoplasms in search

–
Glomerulonephritis, IGA2 of 3 · compare here

Otsuka in Glomerulonephritis, IGA: 1 program

  1. sibeprenlimabphase 3

Their studies: Otsuka’s studies of Glomerulonephritis, IGA in search

Innovent Biologics in Glomerulonephritis, IGA: 2 programs

  1. telitaciceptphase 2
  2. IBI3034phase 1

Their studies: Innovent Biologics’ studies of Glomerulonephritis, IGA in search

–

Show all 23

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Otsuka 7 of 25 · Innovent Biologics 16 of 40 · Sanofi 53 of 80 programs (33 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sanofi: 12).